Keywords: Novartis, Onbrez Breezhaler, Spiriva, COPD, Afinitor, Cell astrocytoma, SEGA, Clinical trials

Novartis’ Onbrez Breezhaler beats Spiriva in new study of COPD patients; Afinitor reduces SEGAs size

Article | 04 November 2010

Print This

Swiss drug major Novartis (NOVN: VX) had a couple of boosts regarding clinical trials, first with its once-daily Onbrez Breezhaler ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in